Densidad del antígeno prostático en el diagnóstico de cáncer de próstata

Samer Houda; Andrea Uncein; Alessandri Espinoza

Authors

Samer Houda Hospital Universitario de Caracas
Andrea Uncein Hospital Universitario de Caracas
Alessandri Espinoza Hospital Universitario de Caracas

Keywords:

PSA density, prostate cancer, rectal examination

Abstract

Prostate cancer is a public health problem worldwide, which is classically suspected due to alteration in prostatic antigen (PSA) and / or rectal examination (RE) and confirmed by prostate biopsy. However, there are other markers such as PSA density (DPSA) that are used to determine the need for a biopsy. Objective: To verify the actual usefulness of PSA density as a diagnostic tool for prostate cancer. Methods: Prospective, descriptive, cross-sectional, the selection of the sample was performed by intentional non-probabilistic sampling, being composed of the number of patients with prostate biopsy criteria who attended the department of urology at University Hospital in Caracas during the months of june -july 2014. Statistical analysis was performed using SPSS / PC Version 25.0 program. Descriptive statistics were used. Results: The study consisted of 100 patients with a mean age of 65 ± 7.7. The detection rate of prostate cancer was 38% taking into account the conventional criteria (PSA and RE), however when the criterion is the DPSA the number of patients was reduced to 33 of which 69.7% (n 23) prostate cancer. Conclusion: The DPSA is a useful tool to be used as a criterion for performing a prostate biopsy overall detection rate of 60.52% which exceeds by itself to conventional screening methods such as the value of PSA and DRE.

Downloads

Download data is not yet available.

References

Ferlay, J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015. 136: E359

Haas, G.P., Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol, 2008. 15: 3866.

Jemal A, Siegle R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. Canc Jour clinic. 2008. 58: 71- 96.

Programa de Oncología. Registro Central de Cáncer. Ministerio del Poder Popular para la Salud de la República Bolivariana de Venezuela. 2015.

Tallada M, Cozar J. Situación actual y perspectivas futuras en el cáncer de próstata. Rev Urol Int Inv. 1998. 3: 3- 6.

Chéchile G, Solé- Balcells F. Cáncer de próstata. Cuadernos de Urología. 1993. 10 (3): 3- 12.

Tanagho E, McAninch J. Urología General de Smith. 14 ed. Manual Moderno. 2009. Pp 363- 385.

Wein A, kavoussi L, Novick A, Partin A, Peters C. Diagnosis and Staging of prostate cancer. Campbell- Walsh Urology, 9th ed. 2009. 4: 2912-25.

Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. 2018. European Association of Urology. EAU guidelines on prostate cancer. 53: 68- 80. 25

Ochiai A, Babaian J. Update on prostate biopsy techinique. Curr Opin Urol. 2004.14: 157-62

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M et al. Guía de la EAU sobre el cáncer de próstata. Act Urol Esp. 2011.35: 501- 14.

Espinoza A, Lavi J, Arenilla W, Houda S, León A. Papel actual de la biopsia prostática guiada por ultrasonido en el diagnóstico de cáncer de próstata. Rev Digit Postgrado. 2018; 7(1): 16-22.

Benavides, L, Borregales L, Boscan E, Capote L, Caricote L, Contreras L, et al. V Consenso Venezolano de enfermedades prostáticas. Caracas: Sociedad Venezolana de Urología, 2012.

León R, Espinoza AR, Polar JL, Houda S, León A. [Evanescent carcinoma of the prostate. Incidence, clinical and histopathological characteristics.] Arch Esp Urol. 2018 Sep; 71(7):583-587.

National Comprehensive Cancer Network. Prostate Cancer (Version 1.2018). http://oncolife.com.ua/doc/nccn/Prostate_Cancer.pdf. Acceso 10 Octubre 2018.

Hubbard H, Folmer M, Khan A and Keys A. Guidelines on Prostate Specific Antigen. American Urological Association. 2013. 109-22.

Ghafoori M, Varedi P, Hosseini S, Asgari M, Shakiba M. Value of prostate specific antigen and prostate specific antigen density in detection of prostate cáncer in an Iranian population of men. Urol Jour. 2009. 6(3): 182-8

Catalona WJ, Smith OS, Ornstein DK. Prostate cáncer detection in men with serum PSA concentrations of 2.6 to 4.0ng/ml and bening prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997. 277: 1452-5

Schöder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V et al. Screening and prostate cancer mortality in a randomized European study. New Engl Jour Med. 2009. 360 (13): 1320- 8.

Carvalhal GF, Smith DS, Mager DE, Ramos C, Catalona WJ. Digital rectal examination for detecting prostate cáncer at prostate specific antigen levels of 4 ng/ml or less. Jour Urol. 1999. 161: 835-839.

Liu X, Tang J, Fei X, Li Q. Prostate specific antigen (PSA) Density and Free to total PSA ratio in diagnosing prostate cáncer with prostate specific antigen levels of 4.0 ng/ml or less. Iran Jour pub Hea. 2015. 44 (11): 1466-1472.

Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men. J Urol. 2017 Feb; 197(2S):S200-S207.

Vásquez L, Fernández A, Cantellano M, Camarena H, Hernández V, Shuck C et al. Validez diagnóstica de la densidad del antígeno prostático en la detección de cáncer de próstata. Rev Mex Urol 2008; 68(4):203-206.

Lam J, Cheung K, Benson M, Goluboff E. Comparison of the predictive accuracy of serum prostate specific antigen levels and prostate specific antigen density in detection of prostate cáncer in Hispanic american and White men. Jour Urol. 2003. 170: 451-456.

Garza M. Importancia de la densidad del APE en el diagnóstico de cáncer de próstata. Rev Mex Urol. 2005;65(6) 427-430

Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000 Aug 1; 56(2):255-60.

Hernández-Medina JA, García-Morata F, Diez-Calzadilla N, Martínez-Jabaloyas JM, Rodriguez-Navarro R, et al. [Clinical characterization of prostate cancer potentially insignificant in the prostate biopsy]. Actas Urol Esp. 2013 Jan; 37(1):27-32.

Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016; 40(2): 244-52.

Potenziani J. PSA Antigeno Prostático Específico. Enfoque. VITAE. 2012. 51: 1- 21.

Verma A, St Onge J, Dhillon K, Chorneyko A. PSA density improves prediction of prostate cáncer. Can Jour Urol. 2014. 21 (3): 7312- 21.